ClinicalTrials.gg
RecruitingNCT07022314Updated Sep 2, 2026

Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®

An observational study in AKI - Acute Kidney Injury, Cardiac Surgery and Fluid Therapy, sponsored by FIZE Medical ltd. Recruiting at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by FIZE Medical ltd · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Acute Kidney Injury with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Acute Kidney Injury · Israel.

Started
2026
the only one that year
Observational
6 of 13
3 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
FIZE Medical ltd

Among the 13 studies in Acute Kidney Injury with a site in Israel, this one is the only one that started in 2026, is one of 6 observational ones, and was the 13th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 13 studies in Acute Kidney Injury with a site in Israel are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute Kidney Injury with a site in Israel, or all of them as a file.
02

Study summary

This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device. The study aims to assess how continuous urine output monitoring can inform fluid management and improve patient outcomes post-cardiac surgery.

Read the detailed description

The study involves adult patients undergoing coronary artery bypass graft (CABG) or valve replacement/repair surgeries. Utilizing the FIZE kUO® device, continuous urine output data will be collected to analyze responses to hemodynamic interventions, including fluid boluses and diuretics. Secondary objectives include assessing urine output differences in patients with and without postoperative acute kidney injury (AKI), responses to vasopressors, and capturing real-time urine output data from FIZE kUO® for observational analysis.

03

Conditions studied

  • AKI - Acute Kidney Injury
  • Cardiac Surgery
  • Fluid Therapy
  • Hemodynamic Instability
  • Postoperative Complications

Keywords

  • FIZE kUO
  • Urine Output
  • Fluid Management
  • Diuretics
  • Cardiothoracic Surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult cardiac surgery patients in the cardiothoracic ICU who require continuous urine output monitoring and are connected to the FIZE kUO® device as part of routine clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years and older scheduled for CABG or valve surgery and expected postoperative admission to CTICU
  2. Ability to provide

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy
  2. Preoperative dialysis (chronic or acute)
  3. Enrollment in other interventional trials assessing urine output or AKI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cardiothoracic ICU Patients

    Adult patients (≥18 years old) undergoing coronary artery bypass graft (CABG) and/or valve surgery, admitted postoperatively to the Cardiothoracic Intensive Care Unit (CTICU), and connected to the FIZE kUO® device for real-time urine output monitoring as part of standard care.

    Device: FIZE kUO®

Interventions

  • DeviceFIZE kUO®

    FIZE kUO® is a commercially available, non-invasive device used for continuous, minute-by-minute real-time urine output monitoring in patients with an indwelling Foley catheter. In this observational study, the device is used during and after cardiac surgery as part of routine clinical care. Urine output data, along with additional clinical parameters, are collected throughout the study for research analysis.

06

What researchers measure

Primary outcomes

  1. Urine output response to fluid boluses and diuretics

    Change in urine output measured by FIZE kUO® during 2 hours before and after fluid or diuretic administration.

    Time frame: 4 hours (2 hours before and 2 hours after intervention)

Secondary outcomes

  1. Difference in urine output during surgery between patients with and without AKI

    Comparison of urine output measured by FIZE kUO® in patients who develop AKI vs. those who do not

    Time frame: Perioperative/Periprocedural

  2. Urine output response to vasopressors

    Change in urine output measured by FIZE kUO® before and after vasopressor administration

    Time frame: 4 hours (2 hours before and 2 hours after intervention)

  3. Evaluation of FIZE kUO® Urine Output Monitoring Compared to Manual Measurement

    Comparison of FIZE kUO® urine output with manual measurement of urine output

    Time frame: Through ICU stay, up to 5 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 365 observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 15, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07022314
Lead sponsor
FIZE Medical ltd
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jan 1, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Rinat Kalaora
Contact
rinat.kalaora@fizemedcial.com
+972-544-750887

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion